Shenzhen YHLO Biotech Co., Ltd.’s RMB 606.8 Million IPO

Appleby’s Hong Kong office acted as Cayman Islands and BVI counsel to Shenzhen YHLO Biotech Co., Ltd. (stock code: 688575) (YHLO Biotech) in relation to its listing on the STAR Market of the Shanghai Stock Exchange on 17 May 2021, with proceeds of approximately RMB 606.8 million.

YHLO Biotech is a leading company of immunoassay solutions in China, specialised in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents for diagnosis of autoimmune diseases, reproductive health, infectious diseases and others. It was founded in 2008 and is headquartered in Shenzhen China.

The Appleby team was led by Counsel Vincent Chan (Picture). 

Involved fees earner: Vincent Chan – Appleby;

Law Firms: Appleby;

Clients: Shenzhen YHLO Biotech Co., Ltd. ;

Author: Sonia Carcano